Viswanatham Katta, PhD
Executive Director, Process Development (part-time)
Viswanatham Katta (PhD, University of Houston) has broad experience in therapeutic protein characterization in general, with an emphasis on mass spectrometry-based techniques of native/reduced/glycosylated/digested mAbs for information on integrity, identity, modifications, variants and host-cell related impurities. He has worked both in Research (Amgen) and Process Development (Genentech and Medivation). He led a group of scientists in the Protein Analytical Chemistry Department that contributed to CMC sections for several INDs of biologics. Dr Katta led the analytical team for ocrelizumab from pre-clinical through phase 1. He also led the CMC team enabling first-in-human clinical trials of a THIOMAB-drug conjugate. He has provided consulting support to CMOs and early-stage biologics companies.